ASRA Fall 2012
Meeting Information
Scientific Information
Support & Exhibition
Useful Links
Bookmark and Share
ASRA 2012 | Pain Medicine & Regional Anesthesia Meeting

Call For Abstracts 

Abstract Submission in Now Closed

Abstract Submission Deadline Extended to August 13, 2012


Please note that there is a submission fee of $25 for each abstract submission.

This payment is non-refundable and is related to abstract submission only. It has no bearing on registration and does not guarantee that the abstract will be accepted for presentation at the 11th Annual Pain Medicine Meeting.

In order to pay this fee you are required to complete the registration process. Please note that you have the option to cancel your Registration and receive a full refund, if you advise the Registration Department before Sep 19th, 2012. 

Abstract Notifications will be sent out in the first two weeks of September, 2012.

If the abstract Presenting Author is different than the participant registering please contact

Instructions regarding Registration and Abstract Submission Payment can be found on the Registration page.


Abstract Topics

Abstracts must be allocated to a specific topic for the scientific program. Please choose from the following topics:

  1. Scientific Abstract 
  2. Medically Challenging Case

Abstracts submitted will be considered for Poster Presentation and all accepted abstracts will be displayed as EPOSTERS.

All abstract submissions will be blind-reviewed. Notification regarding the status (accepted for poster presentation or rejected) will be sent to the presenting author of the abstract by: Mid-September 2012.

The presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission.

Only the abstracts of registered presenting authors will be included in the final program. Abstracts accepted for presentation will be published on the website prior to the meeting.

Abstracts may be submitted for the categories;  Scientific or Medically Challenging.

Abstracts submitted for the category Medically Challenging Cases will be reviewed and scored by the Education Planning Committee. These abstracts are not eligible for the Best of Abstract Award.

Abstracts submitted for the category Scientific will be reviewed and scored by the Research and CME Committee members.

Best OF Abstract Award

The Research Committee will review top 20 scored scientific abstracts and will determine the 3 recipients of the Best of Abstract Award. The highest scored abstract will be presented at the Members Lunch.

The Resident Section Committee Faculty and Education Planning Committee Chair will review the top 10 scored resident identified scientific abstracts and will determine the 3 recipients of the Resident Best of Abstracts Award. These awards will be presented at the Resident Awards and Presentations session of the Resident and Fellow Education Program.

The top scored scientific abstracts will be scheduled as Discussed Poster Presentations in Moderated Poster sessions.


All abstracts must be submitted and presented in English and be of a quality suitable for publication.

Only abstracts of authors who have paid their registration fees by Friday, September 19, 2012 will be scheduled for presentation and included in the program.

The author is expected to attend the meeting and present the poster.

If an abstract was previously submitted to a different meeting it may still be submitted to ASRA 2012.


Before you begin, please prepare the following information:

Presenting Author's Contact Details

  • Full postal address
  • Email address
  • Daytime and evening phone number

Author and Co-Authors' Details

  • Full first and family name(s)
  • Affiliation details: department, institution / hospital, city, state (if relevant), country

Abstract Title
Limited to
25 words in Sentence case

Abstract Text
Limited to
500 words
(Please Note: word count is affected when graphs/tables/images are added)

Abstract Layout
Abstracts must be submitted with the following sections:

  • Introduction
  • Material and methods
  • Results
  • Discussion
  • References
  • Funding

There also should be mention of any funding from grants or by any manufacturer or third-party research funding.

Abstract Topic
Abstracts must be allocated to a specific topic for the scientific program. Please choose from the following topics:

  1. Scientific Abstract 
  2. Medically Challenging Case

The maximum number of tables allowed per abstract is 3. Each table should be smaller than 10 rows x 10 columns. Each row of the table will be counted as 10 words against your 500 word total.

Graphs and Images
For upload max. 2 graphs are allowed. Each graph is counted as 10 words.

The maximum file size of each graph is 500 KB. The maximum pixel size of the graph is 600(w) x 800(h) pixel. You may upload graphs and images in JPG format only.

If your file size or pixel size is too large, you have to resize your graph accordingly.

After uploading the graph you have to place it into the abstract text! It is not mandatory to include a graph into your abstract


The submission form at the link below allows you to store your abstract as a draft in order to make changes. Please note that abstracts must be SUBMITTED before the deadline in order to be sent to review for inclusion in the scientific program.

Please be advised that you will be requested to confirm the following information when you submit your abstract.

  1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published exactly as submitted.
  2. Submission of the abstract constitutes my consent to publication (e.g. meeting website, program, other promotions, etc.)
  3. The Abstract Submitter warrants and represents that he/she is the sole owner or has the rights of all the information and content ("Content") provided to ASRA 2012 and Kenes International (Hereafter: “The Organizers"). The publication of the abstract does not infringe any third party rights including, but not limited to, intellectual property rights.
    The Abstract Submitter grants the Organizers a royalty-free, perpetual, irrevocable nonexclusive license to use, reproduce, publish, translate, distribute, and display the Content.
  4. The Organizers reserve the right to remove from any publication an abstract which does not comply with the above.
  5. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.


Only work that has received local animal or human ethics committee approval as appropriate will be considered for presentation and publication. A statement indicating ethics committee approval has been granted should be incorporated into the abstract and you will be requested to confirm that approval has been applied for/granted before you submit your abstract. When submitting your abstract, please upload your Ethics Committee Approval as a picture or as text pasted into the Abstract text field.

Abstracts which have not received approval will not be accepted - unless they fit into the special categories below.


1. If there are patients involved in the study
2. Anonymous Retrospective Data Collection – unless local committee authorizes otherwise
3. Audit Study – unless local committee authorizes otherwise


1. Questionnaire survey of medical personnel
2. Case studies – with patient consent
3. Literature reviews
4. Historical research
5. Research performed on artificial model
6. Evaluation performed during pre-operative session – with receipt of informed consent


Presentations must be objective and free of commercial bias and any information regarding commercial products or services must be based on scientific methods generally accepted by the medical community. When discussing therapeutic options, speakers are asked to use only generic names. If it is necessary to use a trade name, then those of several companies are to be used. Further, should presentations include discussion of any unlabeled/ investigational use of a commercial product; speakers are required to disclose that information to the audience.

Please choose one option:

  • I declare that there are no conflicts of interest or support that may cause bias in my presentation.
  • I confirm that I am aware of conflicts of interest in my presentation. I agree to declare this conflict of interest at the beginning of my presentation during the meeting.